The document provides a comprehensive overview of Epiphany Biosciences, including its mission, investment thesis, key drug candidates (EPB-348 and EPB-510), clinical trial data, and market potential. EPB-348 is highlighted for its antiviral activity against shingles and EBV, while EPB-510 is noted for its potential in treating Hepatitis C. The document includes detailed clinical trial designs, safety profiles, and market analysis for these drugs.
documents/EFTA00506070.pdf
{}